Studien

IndikationKurzbezeichnungEudra-CT NrPhaseTitel
NHL indolentINCMOR 0208-3012020-004407-13IIIA Phase 3, Randomized, Double-Blind, Placebo-Controlled,
Multicenter Study to Evaluate the Efficacy and Safety of
Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus
Lenalidomide in Addition to Rituximab in Patients With
Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or
R/R Marginal Zone Lymphoma
WaihaIncyte 5046-3092021-002844-66IIIA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of
the Efficacy and Safety of Parsaclisib in Participants With Primary Warm
Autoimmune Hemolytic Anemia
MPNCA011-232020-002071-35Ib/2A Phase 1b Study of BMS-986158 Monotherapy and in Combination with Either Ruxolitinib or Fedratinib in Participants with DIPSS-Intermediate or High Risk Myelofibrosis
Akute LeukämieHaploMUDStudy2017-002331-41IIMatched Unrelated vs. Haploidentical Donor for Allogenic Stem Cell Transplantation in Patients with Acute Leukemia with Identical GVHD- Prophylaxis - A Randomized Prospective European Trial
GVHDMC-MSC.1/aGvHD-IDUNN2019-001462-15IIIA Randomised, Open-label, Multicentre, Phase 3 Trial of First-line Treatment with Mesenchymal Stomal Cells MC0518 Versus Best Available Therapy in Adult and Adolescent Subjects with Steroid-refractory Acute Graft-versus-host Disease After Allogenic Haematopoietic Stem Cell Transplantation (IDUNN Trial)
GVHD GRAPPA2021-000853-17II/IIIGraft vs Host Disease Prophylaxis in unrelated donor transplantation: a randomized clinical trial comparing PTCY vs ATG
AML oder MDS MC-FludT.18/QT2021-005433-16I (Special pharmocological study)Phase I trial to access the cardiac safety of Treosulfan-bases conditioning therapy in subjects with AML or MDS undergoing allogenic hematopoietic stem cell transplantation
Multiples MyelomAlloRelapseMMStudy2021-001005-67IIIAllogenic stem cell transplantation vs. Conventional therapy as salvage therapy for relapsed / progressive patients with multiple myeloma subsequent a first-line therapy
NHL indolentMZoL RegisternafolgtNicht-interventionelles prospektives Register zu Epidemiologie und Behandlungspraxis bei Marginalzonenlymphomen
BasketMK7684A-0042021-001700-15IIA Phase 2, Open-label Study to Evaluate the Safety and Efficacy of MK-7684A (MK-7684 [Vibostolimab] with MK-3475 [Pembrolizumab] Coformulation) in Participants with Relapsed or Refractory Hematological Malignancies
HodgkinHD 212014-005130-55IIIHD 21 for advanced stages. Treatment optimization trial in the first line treatment of advanced stage Hodgkin lymphoma; comparison of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD
NHL aggressivGCT3013-052020-003016-27IIIRandomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma.
NHL aggressivChart ReviewfolgtRetrospective Chart Review for German adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy with subsequent historical comparison against tisagenlecleucel based on the Juliet trial
BasketGenmab 3013
GCT3013-01
2017-001748-36I/IIA Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013
in Patients with Relapsed, Progressive or Refractory B-Cell
Lymphoma
NHLPTLD RegisterfolgtNichtinterventionelle, prospektive Registerstudie zur Behandlungspraxis der PTLD in der klinischen Routine
NHL aggressivDaly2
MB-2020-371
2020-003908-14IIA pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL), who are not eligible for high-dose chemotherapy and autologous stem cell transplantation
NHL aggressivMB-CART2019.1
M-2018-331
2018-001253-27I/IIA Phase I/II safety, dose finding and feasibility trial of MB-CART2019.1 in patients with relapsed or refractory CD20 and CD19 positive B-NHL
NHL aggressivMOR208C310
frontMIND
2020-002990-84IIIA phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the
efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus
R-CHOP in previously untreated, high-intermediate and high-risk patients with newlydiagnosed
diffuse large B-cell lymphoma (DLBCL)
BasketViracta VT3996-202 2020-005197-10IIAn Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Subjects With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (“NAVAL-1”)
ThalassämieEnergize
AG348-C-017
2021-000211-23IIIA Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects with Non–Transfusion-Dependent Alpha- or Beta Thalassemia (ENERGIZE
ThalassämieEnergize T
AG348-C-018
2021-000212-34IIIA Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects with Transfusion-Dependent Alpha- or Beta Thalassemia (ENERGIZE T)
CLLCLL FrailIIA PROSPECTIVE, MULTICENTRE PHASE-II TRIAL OF ACALABRUTINIB
IN VERY OLD (>80Y) OR FRAIL PATIENTS WITH CLL
CLLCLL Registern/afolgtRegistry of the German CLL Study Group: Long term follow-up of patients with CLL, B-PLL, T-PLL, SLL, T/NK-LGL, HCL and Richter´s transformation
CLLCLL 162020-004360-26IITA PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZUMAB AND VENETOCLAX (GVE) IN PREVIOUSLY UNTREATED PATIENTS WITH HIGH RISK (17P-DELETION, TP53- MUTATION OR COMPLEX KARYOTYPE) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
CMLCABL001n/aPhama1st line
ALLGmall Blivenn/aIITAn open label, phase I/II study of Venetoclax in addition to
Blinatumomab immunotherapy in adult patients with relapsed
/refractory B cell precursor acute lymphoblastic leukemia (BCP-ALL)
AMLAML-Registern/aAML-Register und Biomaterialdatenbank der Studienallianz Leukämie (SAL)
AMLTUD-MOSAIC-0752019-003863-23IIMultizentrische Studie mit Phase-I-Teil im 3+3 Studiendesign (MODULE) und
einem randomisiert kontrollierten doppelblinden (MAGNOLIA) und
randomisierten unverblindeten (MAGMA) Phase-II-Teil
AMLRelax2018-003025-28I / IIPhase-I/II trial for relapsed or refractory AML patients
combining cytarabine and mitoxantrone with venetoclax
(RELAX)
AML/MDSPALOMA2018-002430-21IIPrimary comparison of liposomal Anthracycline based treatment versus conventional care strategies before allogeneic cell transplantation in patients with higher risk MDS and oligoblastic AML - the PALOMA study
APLNAPOLEON-RegisterNational Acute Promyelocytic Leukemia (APL) Observational Study Napoleon-Registry of the German AML-Intergroup
ALLGMALL-INITIAL-12016-004836-39IIAn open label phase II study to evaluate the efficacy and safety of inotuzumab ozogamicin for induction therapy followed by a conventional chemotherapy based consolidation and maintenance therapy in patients aged 56 years and older with acute lymphoblastic leukemia (ALL)
ALLALL-RegisterGMALL Register
MPNMPN-Registern/afolgtSAL-MPN-Register und Biomaterieldatenbank der Studienallianz Leukämie (SAL)
MPNBesremi-PASS EUPAS29462AnwendungsbeobachtungA Prospective, Multicentre, Non-interventional,
Observational, Post-authorisation Safety Study of
Ropeginterferon alfa-2b in Polycythaemia Vera Patients
PNHPNH-RegisterfolgtM07-001, 914007 Register für paroxysmale nächtliche Hämoglobinurie (PNH)
PNHBO42161
Commodore 1 switch
2019-004931-21IIIA Phase III, randomized, open-label, active-controlled, multicenter study evaluating the
efficacy and safety of crovalimab versus eculizumab in adult and adolescent patients
with PNH currently treated with complement inhibitors
PNHALXN2040-PNH-3012019-003829-18folgtA Phase 3 Study of Danicopan (ALXN2040) as Add-on Therapy to a C5
Inhibitor (Eculizumab or Ravulizumab) in Patients with Paroxysmal
Nocturnal Hemoglobinuria Who Have Clinically Evident Extravascular
Hemolysis (EVH)”
PNHRavuReWofolgtIIIAnalysis/Outcomes of Patients who switched from being under eculizumab
to ravulizumab treatment in a real-world setting – according to the label
but not included in Phase 3 studies
RavuReWo
WaihaANX-wAIHA-01folgtfolgt“A Study to Evaluate the Complement Signature of Subjects with Warm Autoimmune Hemolytic Anemia “
WaihaMOM-M281-0062019-000720-17II/IIIEfficacy and Safety of M281 in Adults with Warm Autoimmune
Hemolytic Anemia: A Multicenter, Randomized, Double-Blind,
Placebo-Controlled, Study with a Long-term Open-label
Extension
AAEMAA 93452014-000174-19II/IIIEfficacy and Safety of Eltrombopag in Patients with Acquired Moderate Aplastic Anemia (EMAA) who are treated with Ciclosporin A. Prospective Randomized Multicenter Study comparing Thrombopoetin-Receptor agonist Eltrombopag (Revolade ®, GlaxoSmithKline) with Placebo in Patients with Acquired Moderate Aplastic Anemia who are treated with Ciclosporin A
WaihaACT168322020‐003880‐241b + IIA multicenter, open-label, Phase 1b/2 study to evaluate the safety, pharmacokinetics, and efficacy of subcutaneous isatuximab in patients with primary warm autoimmune hemolytic anemia
HämolyseCLNP023L12201IIAn open-label, multi-center, phase 2 basket study to assess efficacy, safety and pharmacokinetics of iptacopan(LNP023) in participants with autoimmune benignhematological disorders
ZNS LymphomeOptimate2018-002115-96IIIOptiMATe - Optimizing MATRix as remission induction for PCNSL: De-escalated induction treatment in newly diagnosed primary CNS lymphoma – a randomized phase III trial“
MMRegeneron 5458-ONC-1826folgtI / IIPHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3
BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR
REFRACTORY MULTIPLE MYELOMA
MM GMMG-CONCEPT2016-000432-17IIEine klinische Phase II Studie zur Induktions-, Konsolidierungs- und Erhaltungstherapie mit Isatuximab, Carfilzomib, Lenalidomid und Dexamethason (I-KRd) in der Primärtherapie des Hochrisikomyeloms
AL-AmyloidoseCAEL101-301IIIA Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis
AL-AmyloidoseCAEL101-302IIIA Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis
AL-AmyloidoseAmyloidose RegisterfolgtNationales klinisches Amyloidose-Register
MMC10710072021-006052-14IIIA RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135)
VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED
MULTIPLE MYELOMA WHO ARE MINIMAL RESIDUAL DISEASE-POSITIVE
AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION